Bavarian Gets Rights to New Cancer Vaccine Product Candidates

Bavarian Nordic A/S said its BN ImmunoTherapeutics subsidiary has agreed with the National Cancer Institute to jointly develop new off-the-shelf product candidates for the treatment of multiple cancers and a new technology platform based on NCI’s cancer vaccine technology.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE